The 2-day difference

Eisai Co. Ltd. and SuperGen Inc. aren’t expressing concern that Dacogen decitabine missed the primary endpoint of survival benefit in a European Phase III trial to treat myelodysplastic syndromes, as the partners maintain the trial used an outdated protocol. Although it’s unclear whether the negative outcome will affect a planned regulatory resubmission in Europe, the companies expect no changes in prescribing habits in the U.S., where the drug is already

Read the full 705 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE